Argenx Se · EURONEXT:ARGX
Argenx — Q1 2025 Earnings Presentation
15 slides from Argenx's earnings presentation, May 8, 2025
Slide 1: Reaching Patients Through Immunology Innovation: Q1 2025 Financial Results Call
Reaching Patients Through Immunology Innovation 1 Q 2 0 2 5 F I N A N C I A L R E S U L T S C A L L M A Y 8 , 2 0 2 5
Slide 2: Forward Looking Statements
Forward Looking Statements This presentation has been prepared by argenx se (“argenx” or the “company”) for informational purposes only and not for any other purpose. Nothing contained in this presentation is, or should be construed as, a recommendation, promise or representation by the presenter or
Slide 3: 2025 Strategic Priorities
Fuel pipeline growth 2025 Strategic Priorities PFS Launch Expand next wave of innovation 4 New Molecules in Phase 1 3 Reach more patients with VYVGART 10 Phase 3s 10 Phase 2s
Slide 4: Maximizing the VYVGART Opportunity
Maximizing the VYVGART Opportunity 4 Geography Pr es en ta tio n C O M M E R C I A L G R O W T H D R I V E R S Pre-Filled Syringe Global Expansion Supporting Earlier Line Use Patient Activation CIDP gMG Label Expansion
Slide 5: VYVGART is Setting a New Standard for Patients
VYVGART is Setting a New Standard for Patients MG1 MSE = MG-ADL SCORE of 0 or 1 ≥ 2 MG-ADL SCORE IMPROVEMENT IN 75% PATIENTS DURING >75% OF VISITS Sustained Efficacy No/minimal symptoms Meaningful response ECI STAGE A CIDP 5 Fred MG Patient Jamilah CIDP Patient Substantial improvement in functional
Slide 6: Significant Milestones through 2026
Significant Milestones through 2026 Regional PFS Approvals 1H25 PFS approval (FDA, EMA) CHMP CIDP Positive Recommendation 2H25 PFS Canada, Japan decisions on approval Efgartigimod IVIg Switch CIDP Ph4 Efgartigimod Seronegative MG Ph3 Efgartigimod Lupus Nephritis Ph2 Empasiprubart DGF Ph2 ARGX-119 CM
Slide 7: Product Net Sales: Q1 of $790 million
Product Net Sales: Q1 of $790 million 21 Q1 2022 Q2 2022 Q3 2022 Q4 2022 Q1 2023 Q2 2023 Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 75 131 173 218 269 329 374 398 478 573 Q1 2025 737 790 China RoW Japan US 7 7 2 14 11 12 20 1 6 11 12 26 24 31 35 45 49 57 2 6 8 10 13 15 17 18 20 24 27 32 21 73 1
Slide 8: Q1 2025 Financial Summary and 2025 Financial Guidance
Q1 2025 Financial Summary 2025 Financial Guidance * Alternative Performance Measure (APM). Refer to the APM Statement. $1.7 billion in cash and cash equivalents and $1.9 billion in current financial assets Ended Q1 with cash* of $3.6B Cash* Driving Growth in Revenue, Profit and Cash Flow Three month
Slide 9: Innovation has no value unless it provides meaningful benefit to patients
Innovation has no value unless it provides meaningful benefit to patients 9 Mike, MG Patient
Slide 10: Strong Launch Fundamentals Driving Expansion
Strong Launch Fundamentals Driving Expansion US Reaching Patients Earlier M G P A T I E N T G R O W T H Consistent QoQ New Patient Starts Continued Launch Momentum C I D P P A T I E N T G R O W T H Breadth of prescribers 3,700 Neurologists in the US P R E S C R I B E R E X P A N S I O N Available in
Slide 11: Optimal Label for VYVGART Hytrulo Pre-filled Syringe
11 Optimal Label for VYVGART Hytrulo Pre-filled Syringe Bringing Independence and Flexibility to Patients I don’t want to be a prisoner to my disease or treatment…I am ready to take control back of my life. I’m ready to travel and do things with my family without being weighed down by having to go t
Slide 12: Activating an Empowered Patient Community
Activating an Empowered Patient Community 12
Slide 13: Strong Growth Trajectory to 50K Patients
Wave 2 (2026-2027) Wave 3 (2028-2030)Wave 1: TODAY TED Myositis oMG snMG Sjogren’s gMG CIDP ITP DM MMN CMS CIDP 50K 13 Strong Growth Trajectory to 50K Patients VYVGART Empasiprubart ARGX-119
Slide 14: Vision 2030
14 Vision 2030 COMMITMENT TO OUR INNOVATION MISSION 5 New Molecules in Phase 3 10 Labeled Indications 50k Patients on Treatment
Slide 15: Alternative Performance Measure
Alternative Performance Measure In this document, argenx's financial results are provided in accordance with IFRS® Accounting Standards (IFRS) and using a non-IFRS financial measure, Cash, cash equivalents and current financial assets. This value should not be viewed as a substitute for the company’